Krish Krishnan
Chairman & CEO

CEO - Krish Krishnan

Krish Krishnan
Chairman & CEO

Krish Krishnan is an accomplished biotech executive. He was specifically involved in two successful IPOs (COO/CFO of New River Pharmaceuticals, Inc., NASDAQ: NRPH) and COO of Intrexon Corporation, Inc., NYSE: XON), approval of the blockbuster drug Vyvanse (for ADHD in 2007) and the sale of New River Pharmaceuticals, Inc. to Shire Pharmaceuticals, plc for $2.6BN. He served as the CEO of Pinnacle Pharmaceuticals, Inc. and advanced a potential treatment for urinary tract infection from discovery to Phase II. He has served as Board member for Biotie Therapies Oyi (BTH1V: Helsinki, NASDAQ: BITI), a specialized drug development company in Finland and Thar Pharmaceuticals, Inc. prior to its sale to Grunenthal GmbH in 2017. Previously, Krish served as a Managing Principal of Suppliermarket.com (a pharmaceutical B2B marketplace) that was sold to Ariba in 2001 for $500M. Krish started his career as a Senior Engineer at E.I. Dupont de Nemours. Krish has an undergraduate degree from the Indian Institute of Technology and a graduate degree in Finance from The Wharton School at University of Pennsylvania.

Suma Krishnan
President, Research & Development

President, Research & Development - Suma Krishnan

Suma Krishnan
President, Research & Development

Suma Krishnan has 25 years of drug development experience and has delivered on multiple gene therapy programs from discovery to the clinic as Head of Therapeutics at Intrexon Corporation (NYSE: XON). Previously, she led the discovery, development, and approval of Vyvanse™ (blockbuster drug to treat ADHD) as SVP, Product Development at New River Pharmaceuticals. Prior to that, Suma advanced approval of Adderall XR® and Fosrenol® at Shire. She began her career as a discovery scientist for Janssen Pharmaceuticals, Inc. Suma has over 20 publications and 20 issued US patents. She received her Master of Science in Organic Chemistry from Villanova University, an M.B.A. from Institute of Management and Research, and an undergraduate degree in Organic Chemistry from Ferguson University.

Kathryn Romano
EVP & Chief Accounting Officer

EVP & Chief Accounting Officer - Kathryn Romano

Kathryn Romano
EVP & Chief Accounting Officer

Kathryn Romano was named Chief Accounting Officer in February 2020. Kathryn most recently held the position of Corporate Controller at CNX Resources Corporation. Prior to joining CNX, Kathryn was the Corporate Controller of Rice Energy from January 2013 until the company was acquired by EQT in November 2017, staying on to assist the company through the transition until March 2018. Prior to joining Rice Energy, Kathryn worked in a variety of accounting and auditing roles at Black Box Corporation and Deloitte. Kathryn is a Certified Public Accountant and holds a Bachelor of Science in Accounting from Penn State University.

Laurent Goux
SVP & General Manager Europe

SVP & General Manager Europe - Laurent Goux

Laurent Goux
SVP & General Manager Europe

Laurent Goux is SVP and General Manager Europe, leading the Krystal Team in that region. Prior to joining Krystal, Laurent worked for almost 20 years in dermatology at Galderma with broad international experience through various leadership roles as Global Head of Strategic Marketing and Market Access, Regional Director of Central and Eastern Europe, General Manager of Australia and NZ, and as an international finance leader. He graduated as a Chemical Engineer in Bordeaux and holds a Master’s in Strategy and Management of International Business Management from ESSEC school in Paris.

Jennifer McDonough
SVP, Patient Access, Analytics and Operations

VP, Business Development - Stephane Paquette

Jennifer McDonough
SVP, Patient Access, Analytics and Operations

Jennifer McDonough was named SVP, Patient Access, Analytics and Operations in February 2024. Jennifer is a highly accomplished biopharmaceutical leader with over 25 years of experience in the commercialization and launch of specialty and rare disease therapies. Prior to joining Krystal, Jennifer served as VP, Market Access, Patient Services & Distribution at Strongbridge BioPharma where she led the operational build for three successful launches in rare neuromuscular and rare endocrine therapeutic areas. Prior to Strongbridge, Jennifer was VP, Commercialization Strategy & Business Development with AmerisourceBergen (now Cencora) where she focused on supporting emerging biopharma companies defining patient service and distribution solutions. Before AmerisourceBergen, Jenifer was at EMD Serono leading specialty pharmacy strategy and account management across all therapeutic areas including neurology, oncology, and immunology. She began her biopharma career at CVS Health/Specialty Pharmacy. Jennifer completed her Masters in Secondary Math Education at the University of Pittsburgh. She also holds a BS in Mathematics and Computer Science from the University of Pittsburgh.

Christine Wilson
Head of U.S. Sales and Marketing

Head of U.S. Sales and Marketing - Christine Wilson

Christine Wilson
Head of U.S. Sales and Marketing

Christine Wilson is Head of U.S. Sales and Marketing at Krystal. Christine is an experienced industry leader with a demonstrated history of performance in different therapeutic areas and sales models including specialty, buy-and-bill, medical device and the rare disease space. Prior to joining Krystal, Christine was Vice President, U.S. Sales at Travere Therapeutics where she managed the sales force with hands-on leadership experience. Before joining Travere, Christine held the position of Head of Sales, Nephrology at Reata Pharmaceuticals, Inc. and at Shire where she held many different roles including sales training, sales operations, patient advocacy and various sales leadership roles, including Vice President of the U.S. for the GI Sales Team. Christine began her career at Merck as a Professional Sales Representative. Christine holds a Bachelor of Science degree in Marketing from Penn State University.

Hiroshi Kasamoto
General Manager Japan

General Manager Japan - Hiroshi Kasamoto

Hiroshi Kasamoto
General Manager, Japan

Hiroshi Kasamoto is General Manager Japan, leading the launch of Krystal’s business in the region. Hiroshi has more than 30 years of marketing and commercial experiences leading various successful launches for both rare disease and primary products. Prior to joining Krystal, he served as Head of RBD at Sanofi where he led Japanese operation in rare blood disorders. Before Sanofi, Hiroshi also demonstrated his leadership at Biogen and Bioverativ, its spin-off where he served as CEO of Japan affiliate and managed the entire business function. Through his career, Hiroshi has largely contributed to a various new drug launches especially in rare disease space. Hiroshi has devoted himself to making a paradigm shift in both therapeutic and healthcare strategies through new drug launches in therapeutic areas of high unmet medical needs with no treatment.

David Chien
SVP, Clinical Development

SVP, Clinical Development - David Chien

David Chien
SVP, Clinical Development

David Chien is SVP, Clinical Development at Krystal Biotech, Inc. David brings over a decade of experience across all phases of drug development. Prior to joining Krystal, David was the Executive Medical Director at Nektar, leading the global development of bempegaldesleukin, an immune-oncology program with multiple registrational trials in solid tumor indications. Prior to Nektar, David worked with Amgen, leading global development of oncology and rare disease biosimilars, including Riabni through submission for FDA approval. At AbbVie, David led early clinical development of lymphoma indications for Venclexta. David holds a Doctor of Medicine from the University of California, Davis. David completed his medical training in Internal Medicine internship at New York Hospital Queens, Nuclear Medicine residency and PET/CT fellowship at The John Hopkins Hospital.

Ramesh Arjunji
SVP, Global Value and Access

Senior Vice President, Global Value and Access - Ramesh Arjunji

Ramesh Arjunji
SVP, Global Value and Access

Ramesh Arjunji is SVP, Global Value and Access at Krystal. Prior to joining Krystal, Ramesh was Vice President and Head, Evidence Synthesis at SSI Strategy where he advised clients on evidence generation strategies to support pipeline product value proposition for commercial success. Before joining SSI Strategy, Ramesh was VP, Value & Access at Avrobio and led the development and execution of evidence generation strategies for lentiviral based lysosomal storage disorders gene therapy products in development. Ramesh has also had experience at AveXis/Novartis Gene Therapies as well as GSK, Alcon, BMS, Biogen, Pfizer, Endo Pharmaceuticals, and Centocor/J&J, covering oncology, global business analytics, payer market research, payer marketing, marketing science, commercial strategy & portfolio planning, and health outcomes. Ramesh received a BS in Aeronautics from Indian Institute of Technology, Kanpur, MS in Mechanical Engineering from Florida State University, Tallahassee, and a Ph.D. in Management Science from the University of Texas at Dallas.

John Thomas
General Counsel & Corporate Secretary

General Counsel & Corporate Secretary - John Thomas

John Thomas
General Counsel & Corporate Secretary

John Thomas is General Counsel and Corporate Secretary at Krystal. Before Krystal, he was a partner at the Webb Law Firm. John has represented pharmaceutical companies as well as other fortune 500 companies with regard to litigation and intellectual property matters. John was a founder and former managing partner of Beck & Thomas, P.C. He was named in Best Lawyers in America from 2016-2022 for Intellectual Property law (litigation) Pittsburgh, PA, 2017-2022 Patent Law and Trademark law, Pittsburgh, and was the Best Lawyers in America 2018 Trademark Lawyer of the Year–Pittsburgh PA. He holds a B.S. in Chemistry from Indiana University of Pennsylvania and a J.D. from Duquesne Law, Cum Laude. John was an Associate Recent Decisions Editor of the Duquesne Law Review.

Trevor Parry
VP, Research and Scientific Affairs

VP, Research and Scientific Affairs - Trevor Parry

Trevor Parry
VP, Research and Scientific Affairs

Trevor Parry manages Krystal’s intellectual property portfolio, providing patent prosecution and counseling in both the US and foreign jurisdictions, as well as advising on IP management and licensing. Prior to joining Krystal, Trevor was a patent agent in Morrison & Foerster LLP’s Life Sciences Group, with a focus on gene and antibody therapeutics, vaccines, and pharmaceutical manufacturing. Trevor’s practice included coordinating patent prosecution and strategies in the US, Europe, Asia, and Australia. Trevor has extensive experience in patent drafting and prosecution, IP due diligence and landscape reviews, and freedom-to-operate analyses. Trevor received a B.S. in biochemistry/cell biology, as well as an M.S. in biology with an emphasis on biochemistry, from the University of California, San Diego. Trevor received his Ph.D. in molecular biology from the Department of Microbiology and Immunology at the University of California, San Francisco. His doctoral research focused on innate immunity and the interplay between bacterial pathogens and host cell signaling, incorporating work in bacterial and mammalian genetics with large-scale animal studies. In his off time, Trevor loves to travel, fly fish, and homebrew beer. Bar admission: U.S. Patent & Trademark Office

Stéphane Paquette
VP, Business Development

VP, Business Development - Stephane Paquette

Stéphane Paquette
VP, Business Development

Stéphane Paquette is VP of Business Development at Krystal Biotech where he leads partnering activities for the company. Stéphane brings over 14 years of life sciences research and business development experience to the team. Prior to joining Krystal, Stéphane served as VP of Corporate Development at Appili Therapeutics, a biopharmaceutical company focused on infectious diseases. Stéphane was responsible for R&D portfolio strategy, search and evaluation, alliance management, and led business development efforts to grow Appili’s pipeline to five programs including multiple Phase 2/3 assets. He is an author on 14 peer-reviewed publications in virology, immunology, and biochemistry and holds a PhD from the University of Toronto with a BSc in Microbiology & Immunology from McGill University.

Mark A. Petrich
VP, Process Development and Validation

Vice President, Process Development and Validation - Mark Petrich

Mark A. Petrich
VP, Process Development and Validation

Mark Petrich is Vice President, Process Development and Validation at Krystal Biotech, Inc. Before joining Krystal, Mark held leadership roles at Merck & Co. in single-use systems engineering, pilot plant operations, supplier relationship management, and laboratory automation engineering. Mark is active in professional organizations and currently serves as chair of the BioProcess Systems Alliance (BPSA) board of directors. He has been a frequent speaker at industry events and has co-authored over 50 publications. Mark received the BioProcess International “Industry Champion” award for promoting collaborative efforts in design, qualification, and application of single use technologies in biopharmaceutical manufacturing. Mark started his career in the Chemical Engineering department at Northwestern University where he was the M.E. Fine Junior Professor of Materials and Manufacturing. Mark is licensed Professional Engineer and holds degrees in Chemical Engineering from Washington University (BS) and University of California, Berkeley (PhD).

Felino Obillo
VP, Global Supply Chain

Vice President of Global Supply Chain - Felino Obillo

Felino Obillo
VP, Global Supply Chain

Felino Obillo is Vice President of Global Supply Chain at Krystal. Felino is a performance-focused leader with 25+ years of experience specializing in driving operations growth, building solid teams, creating cost-reducing process improvements, and cultivating an environment of top manufacturing quality. Prior to joining Krystal, Felino held various roles of increasing responsibility at Viatris (Mylan) including site manufacturing, global operations, and third-party management. As Sr Director Manufacturing of Global Biologics, Global Key Brands, and Respiratory he was responsible for standing up the global supply chain for Viatris’ biosimilar program and was part of the team that brought the First US-FDA approved biosimilars for Trastuzumab and Peg-filgrastim and the First Interchangeable Biosimilar for Insulin with Semglee to the United States along with other products approved around the world such as the EU-approved Hulio biosimilar to Adalimumab. Before joining Mylan, Felino began his career at Epoch Biosciences (Synthetic Genetics) an oligonucleotide manufacturer. Felino holds a BS in Biology from Revelle College at University of California, San Diego.

Discovering, developing, and commercializing genetic medicines with purpose

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed

Krystal Biotech Logo
You are now leaving www.krystalbio.com
Links to sites outside of this website are provided as a resource to the viewer.
Krystal Biotech accepts no responsibility for the content of linked sites.

Proceed